Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025 ...Middle East

HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line...

Hence then, the article about updated efficacy data of ivonescimab combined with chemotherapy as first line treatment for tnbc presented at esmo io 2025 was published today ( Thursday 11/12/2025 - 05:00 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025 )

Also on site :

• Road over canal in Penkridge closed as bridge reportedly collapses
• Disneyland Paris New Year’s Eve Fireworks Live Stream 2025–2026: Watch Here
• Police and air ambulance attend 'medical emergency' incident in Stourbridge